|
21 Dec 2021 |
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
|
|
21 Dec 2021 |
FDA approves Otezla (apremilast) for the treatment of adult patients with plaque psoriasis, regardless of severity level
|
|
20 Dec 2021 |
ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases
|
|
20 Dec 2021 |
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
|
|
17 Dec 2021 |
Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
|
|
17 Dec 2021 |
Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day
|
|
17 Dec 2021 |
Albireo Announces Positive Topline Data from Phase 1 Study of A3907
|
|
17 Dec 2021 |
Basilea announces FDA approval of Investigational New Drug application for novel oncology drug candidate BAL0891
|
|
17 Dec 2021 |
EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate
|
|
16 Dec 2021 |
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
|
|
16 Dec 2021 |
Artax Biopharma Announces First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company's First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
|
|
15 Dec 2021 |
Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo
|
|
15 Dec 2021 |
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
|
|
15 Dec 2021 |
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
|
|
14 Dec 2021 |
LEO Pharma Initiates a Phase 2b Dose-Ranging Clinical Trial With an Oral H4R Antagonist in Adult Patients With Moderate-to-Severe Atopic Dermatitis (AD)
|
|
14 Dec 2021 |
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
|
|
14 Dec 2021 |
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
|
|
14 Dec 2021 |
Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
|
|
14 Dec 2021 |
ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
|
|
13 Dec 2021 |
Sparrow Pharmaceuticals Announces FDA Clearance of IND for SPI-62 for the Treatment of Cushing’s Disease
|
|
13 Dec 2021 |
Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting
|
|
12 Dec 2021 |
Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting
|
|
12 Dec 2021 |
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting
|
|
10 Dec 2021 |
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
|
|
10 Dec 2021 |
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
|
